These results shed light on the mechanisms of GRK6‐P2Y6 signaling in ACC in the development of visceral hypersensitivity and provide a new therapeutic avenue into the treatment of chronic visceral hypersensitivity in patients with IBS. The gene discussed is P2RY6; the disease is irritable bowel syndrome.